219 related articles for article (PubMed ID: 17472819)
21. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
22. Dose selection for glycopyrrolate/eFlow
Donohue JF; Goodin T; Tosiello R; Wheeler A
Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study.
Kuna P; Ivanov Y; Trofimov VI; Saito T; Beckman O; Bengtsson T; Jorup C; Maltais F
Respir Res; 2013 Jun; 14(1):64. PubMed ID: 23731768
[TBL] [Abstract][Full Text] [Related]
24. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.
Chan CK; Maltais F; Sigouin C; Haddon JM; Ford GT;
Can Respir J; 2007; 14(8):465-72. PubMed ID: 18060091
[TBL] [Abstract][Full Text] [Related]
25. Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Fahy WA; Homayoun-Valiani F; Cahn A; Robertson J; Templeton A; Meeraus WH; Wilson R; Lowings M; Marotti M; West SL; Tabberer M; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1637-1646. PubMed ID: 34113095
[TBL] [Abstract][Full Text] [Related]
26. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD.
Borrill ZL; Houghton CM; Tal-Singer R; Vessey SR; Faiferman I; Langley SJ; Singh D
Br J Clin Pharmacol; 2008 Feb; 65(2):244-52. PubMed ID: 18251761
[TBL] [Abstract][Full Text] [Related]
27. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.
Westwood M; Bourbeau J; Jones PW; Cerulli A; Capkun-Niggli G; Worthy G
Respir Res; 2011 Apr; 12(1):40. PubMed ID: 21477298
[TBL] [Abstract][Full Text] [Related]
28. Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study.
Le Rouzic O; Picaud M; Salvator H; Bautin N; Devillier P; Perez T
Respir Med Res; 2024 Jun; 85():101082. PubMed ID: 38280281
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease.
Chuck A; Jacobs P; Mayers I; Marciniuk D
Can Respir J; 2008; 15(8):437-43. PubMed ID: 19107245
[TBL] [Abstract][Full Text] [Related]
30. Atomization efficacy of a novel micro-dose mesh nebulizer (CVS-100) versus the traditional mesh nebulizer (M102) in adults with chronic obstructive pulmonary disease: A randomized non-inferiority clinical trial.
Qu Y; Gong Y; Li L; Song Y; Song Y; Hou D; Hu L
Respir Med; 2023; 219():107434. PubMed ID: 37879448
[TBL] [Abstract][Full Text] [Related]
31. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.
Donohue JF; Ferguson GT; Ohar JA; Lombardi DA; Schneider RF; Johnson K
Respir Med; 2023 Mar; 208():107123. PubMed ID: 36681255
[TBL] [Abstract][Full Text] [Related]
32. Demographic, physiologic and radiographic characteristics of COPD patients taking chronic systemic corticosteroids.
Swift I; Satti A; Kim V; Make BJ; Newell J; Steiner RM; Wilson C; Murphy JR; Silverman EK; Criner GJ;
COPD; 2012 Feb; 9(1):29-35. PubMed ID: 22292596
[TBL] [Abstract][Full Text] [Related]
33. Inhaled β-agonist does not modify sympathetic activity in patients with COPD.
Haarmann H; Mohrlang C; Tschiesner U; Rubin DB; Bornemann T; Rüter K; Bonev S; Raupach T; Hasenfuß G; Andreas S
BMC Pulm Med; 2015 Apr; 15():46. PubMed ID: 25924990
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Mariotti F; Govoni M; Lucci G; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3399-3410. PubMed ID: 30425469
[TBL] [Abstract][Full Text] [Related]
35. QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies.
Chapman KR; Bateman ED; Chen H; Hu H; Fogel R; Banerji D
Chronic Obstr Pulm Dis; 2015 Jan; 2(1):48-60. PubMed ID: 28848830
[No Abstract] [Full Text] [Related]
36. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.
Calverley PMA; Sethi S; Dawson M; Ward CK; Finch DK; Penney M; Newbold P; van der Merwe R
Respir Res; 2017 Aug; 18(1):153. PubMed ID: 28793896
[TBL] [Abstract][Full Text] [Related]
37. Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Martinez FJ; Criner GJ; Gessner C; Jandl M; Scherbovsky F; Shinkai M; Siler TM; Vogelmeier CF; Voves R; Wedzicha JA; Bartels C; Bottoli I; Byiers S; Cardenas P; Eckert JH; Gutzwiller FS; Knorr B; Kothari M; Parlikar R; Tanase AM; Franssen FME
Am J Respir Crit Care Med; 2023 Aug; 208(4):417-427. PubMed ID: 37411039
[No Abstract] [Full Text] [Related]
38. Prediction of Treatment Response in Patients with Chronic Obstructive Pulmonary Disease by Determination of Airway Dimensions with Baseline Computed Tomography.
Park HJ; Lee SM; Choe J; Lee SM; Kim N; Lee JS; Oh YM; Seo JB
Korean J Radiol; 2019 Feb; 20(2):304-312. PubMed ID: 30672170
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.
Bajwa EK; Cislak D; Kumar A; Li D; Messina EJ; Reynders T; Denef JF; Corcea V; Buch KP; Lai E; Stoch SA
Int J Chron Obstruct Pulmon Dis; 2024; 19():1105-1121. PubMed ID: 38803412
[TBL] [Abstract][Full Text] [Related]
40. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.
Feldman GJ; Bernstein JA; Hamilton A; Nivens MC; Korducki L; LaForce C
Springerplus; 2014; 3():419. PubMed ID: 25187881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
